CUE - Cue Biopharma, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD
7.01
-0.13 (-1.85%)
As of 1:29PM EDT. Market open.
Stock chart is not supported by your current browser
Previous close7.14
Open7.16
Bid7.00 x 900
Ask7.07 x 1100
Day's range6.87 - 7.16
52-week range4.16 - 12.00
Volume25,520
Avg. volume82,785
Market cap145.649M
Beta (3Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-2.11
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est14.50
Trade prices are not sourced from all markets
  • Do Insiders Own Shares In Cue Biopharma, Inc. (NASDAQ:CUE)?
    Simply Wall St.11 days ago

    Do Insiders Own Shares In Cue Biopharma, Inc. (NASDAQ:CUE)?

    The big shareholder groups in Cue Biopharma, Inc. (NASDAQ:CUE) have power over the company. Generally speaking, as a...

  • GlobeNewswire2 months ago

    Cue Biopharma to Present Corporate Overview & Clinical Strategy for CUE-101 at Jefferies 2019 Healthcare Conference

    Cue Biopharma, Inc., (CUE) an innovative clinical stage immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today it will present a corporate overview and update at the Jefferies 2019 Healthcare Conference on Thursday, June 6, 2019 at 3:00 pm ET in New York City. Daniel Passeri, M.Sc., J.D., President and Chief Executive Officer, will provide an overview of the translational-based clinical strategy for the Company’s lead program CUE-101, that recently received IND acceptance from the FDA. The presentation will also be archived for 30 days on the Investors section of the Company's website at www.cuebio.com.

  • GlobeNewswire2 months ago

    Cue Biopharma to Host Business Update Call and Webcast

    Cue Biopharma, Inc., (CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today it will host a conference call and webcast to provide a business update on May 21, 2019 at 4:30 pm ET. Live and archived versions of the event can be accessed via the Company’s website. Members of the Cue Biopharma executive management team will provide an update on the Company’s platform and pipeline progress, as well as updates on its strategic objectives and anticipated milestones.

  • GlobeNewswire2 months ago

    Cue Biopharma Announces FDA Acceptance of IND for Lead Immuno-oncology Candidate, CUE-101, in Treatment of HPV-driven Cancers

    Cue Biopharma, Inc., (CUE), an innovative clinical stage immunotherapy company, developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application for its lead immuno-oncology candidate, CUE-101, an Immuno-STAT™ (Selective Targeting and Alteration of T cells) biologic, as a potential treatment for HPV-associated cancers. “FDA acceptance of our IND filing for CUE-101 is an important step toward validating our approach for selective modulation of disease-relevant T cells directly in patients with an “off-the shelf” biologic.

  • GlobeNewswire2 months ago

    Dr. Anish Suri, Cue Biopharma’s CSO, to Participate in Panel Discussion at Upcoming NYAS Frontiers in Cancer Immunotherapy Conference

    Cue Biopharma, Inc., (CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today Anish Suri, Ph.D., Senior Vice President and Chief Scientific Officer will participate in a panel discussion entitled “Novel Approaches from Biotech,” Session 4, Breakout Track A, at The New York Academy of Sciences (NYAS), Frontiers in Cancer Immunotherapy Conference on Wednesday, May 15 at 1:00 PM ET in New York. Dr. Suri will discuss the Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform, including mechanistic data demonstrating the specificity and selectivity of the Immuno-STAT biologics framework and its ability to target tumor-specific T cells and activate them into potent cytotoxic killer T cells.

  • If You Had Bought Cue Biopharma (NASDAQ:CUE) Stock A Year Ago, You'd Be Sitting On A 25% Loss, Today
    Simply Wall St.3 months ago

    If You Had Bought Cue Biopharma (NASDAQ:CUE) Stock A Year Ago, You'd Be Sitting On A 25% Loss, Today

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is doubtless a positive to see that the Cue Biopharma, Inc. (NASDAQ:CUE) share price has gained...

  • GlobeNewswire3 months ago

    Cue Biopharma to Present Immuno-STAT Platform Technology at PEGs Boston 2019

    CAMBRIDGE, Mass., April 08, 2019 -- Cue Biopharma, Inc. (NASDAQ: CUE), an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to.

  • GlobeNewswire4 months ago

    Cue Biopharma to Present Corporate Overview and Update at the Oppenheimer 29th Annual Healthcare Conference

    Cue Biopharma, Inc., (CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today that it will present a corporate overview at the Oppenheimer 29th Annual Healthcare Conference on Tuesday, March 19, 2019 at 10:20 am ET, at the Westin New York Grand Central in New York City. Daniel Passeri, M.Sc., J.D., President and Chief Executive Officer, will provide an update on the Company’s Immuno-STAT™ platform and pipeline progress for the Cue-100 series.

  • GlobeNewswire5 months ago

    Cue Biopharma to Present Corporate Update at 2019 BIO CEO & Investor Conference

    Cue Biopharma, Inc., (CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today that it will be presenting an update at the BIO CEO & Investor Conference on Tuesday, February 12, 2019, at 10:00 am ET (Hudson/Empire Room), at the New York Marriott Marquis Hotel, NY.  Daniel Passeri, M.Sc., J.D., President and Chief Executive Officer, will provide an overview of the Company's Immuno-STAT™ platform and development strategy as well as pre-clinical data updates on key programs and anticipated milestones. This design enables Immuno-STAT Biologics to engage with the T cell population of interest, resulting in highly targeted T cell modulation.

  • Cue Biopharma, Inc. (NASDAQ:CUE) Insiders Increased Their Holdings
    Simply Wall St.6 months ago

    Cue Biopharma, Inc. (NASDAQ:CUE) Insiders Increased Their Holdings

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more Read More...

  • GlobeNewswire6 months ago

    Cue Biopharma Announces Presentation Highlighting Immuno-STAT Platform and CUE-101 at the 2019 Keystone Symposia Conference

    CAMBRIDGE, Mass., Jan. 16, 2019 -- Cue Biopharma, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to.

  • GlobeNewswire7 months ago

    Cue Biopharma and LG Chem Life Sciences Announce WT1 as the Next Immuno-STAT™ Target in Oncology

    Cue Biopharma™, Inc., (CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate antigen-specific T cells to treat cancer, autoimmune and chronic infectious diseases, along with LG Chem Life Sciences, announced today the selection of Wilms’ Tumor 1 (WT1) as the target antigen for CUE-102, pursuant to the partners’ strategic research and development agreement.

  • GlobeNewswire8 months ago

    Cue Biopharma Presents Foundational Data on Immuno-STAT Platform and CUE-101 at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

    Cue Biopharma™, Inc., (CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to modulate antigen-specific T cells to treat cancer, autoimmune and chronic infectious diseases, announced today preclinical results demonstrating the potential of its Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform and lead candidate CUE-101. The poster, entitled “CUE-101, a novel Fc fusion protein comprised of HLA-A*0201-bound HPV16 E7 peptide and IL-2, for selective targeting and expansion of anti-tumor T cells for treatment of HPV-driven malignancies,” (P185) is being presented today during the poster session at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting being held in Washington, D.C.

  • GlobeNewswire8 months ago

    Cue Biopharma Announces Strategic Collaboration with LG Chem Life Sciences for Immuno-STAT™ Biologics in Oncology

    Collaboration Expands Development and Manufacturing of Immuno-STAT™ Biologics and Broadens Coverage of Patient Populations CAMBRIDGE, Mass., Nov. 08, 2018 -- Cue Biopharma™,.

  • GlobeNewswire9 months ago

    Cue Biopharma Announces Presentation at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

    CAMBRIDGE, Mass., Oct. 30, 2018 -- Cue Biopharma™, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to.

  • Simply Wall St.9 months ago

    What Kind Of Shareholders Own Cue Biopharma Inc (NASDAQ:CUE)?

    The big shareholder groups in Cue Biopharma Inc (NASDAQ:CUE) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their Read More...